Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1I2 | O75469 | 5/20 | 0.60 |
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
| ▸ | SERPINE1 | P05121 | 4/20 | 0.46 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.44 |
| ▸ | KIT | P10721 | 1/20 | 0.43 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.42 |
| ▸ | DRD2 | P14416 | 2/20 | 0.42 |
| ▸ | DRD3 | P35462 | 2/20 | 0.42 |
| ▸ | HTR6 | P50406 | 2/20 | 0.42 |
| ▸ | METAP2 | P50579 | 1/20 | 0.42 |
| ▸ | HTR2A | P28223 | 1/20 | 0.41 |
| ▸ | HTR2C | P28335 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1810608 | 0.86 | BRD4 (0.55) | MAPTSERPINE1TRIM24 | |
| SCHEMBL1811184 | 0.84 | NR1I2 (0.58) | NR1I2ATMSERPINE1MEN1KMT2A | |
| SCHEMBL1843607 | 0.83 | PKM (0.50) | NR1I2MAPTSERPINE1PDE3AMEN1 | |
| SCHEMBL1811589 | 0.83 | TRIM24 (0.50) | NR1I2MAPTSERPINE1PDE3AMEN1 | |
| SCHEMBL1819641 | 0.82 | PGR (0.57) | MAPTSERPINE1 | |
| SCHEMBL3915102 | 0.81 | PTGDR2 (0.48) | NR1I2MAPTSERPINE1PDE3AMEN1 | |
| SCHEMBL1807831 | 0.80 | PGR (0.53) | MAPTFFAR4TRIM24 | |
| SCHEMBL3911015 | 0.80 | PPARG (0.44) | NR1I2MAPTSERPINE1 | |
| SCHEMBL4353879 | 0.80 | HPGD (0.51) | MAPTMEN1KMT2A | |
| SCHEMBL1807440 | 0.79 | NR3C1 (0.51) | MAPTSERPINE1MEN1KMT2AHTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4682207-B2 | — | — | 2011-05-11 | — | — | JP | claimed |
| US-7528158-B2 | Indazolone derivatives useful as 11b-HSD1 inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2009-05-05 | — | — | US | claimed |
| EP-1797042-B1 | INDOZOLONE DERIVATIVES AS 11B-HSD1 INHIBITORS | HOFFMANN LA ROCHE (CH) | 2009-01-07 | — | — | EP | claimed |
| EP-1797042-A1 | INDOZOLONE DERIVATIVES AS 11B-HSD1 INHIBITORS | F.HOFFMANN-LA ROCHE AG (CH) | 2007-06-20 | — | — | EP | claimed |
| WO-2006034804-A1 | INDOZOLONE DERIVATIVES AS 11B-HSD1 INHIBITORS | F.HOFFMANN-LA ROCHE AG (CH) | 2006-04-06 | — | — | WO | claimed |
| US-20060069269-A1 | Novel indazolone derivatives useful as 11b-HSD1 inhibitors | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2006-03-30 | — | — | US | claimed |
| US-7528158-B2 | Indazolone derivatives useful as 11b-HSD1 inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2009-05-05 | — | — | US | disclosed |
| EP-1797042-B1 | INDOZOLONE DERIVATIVES AS 11B-HSD1 INHIBITORS | HOFFMANN LA ROCHE (CH) | 2009-01-07 | — | — | EP | disclosed |
| EP-1797042-A1 | INDOZOLONE DERIVATIVES AS 11B-HSD1 INHIBITORS | F.HOFFMANN-LA ROCHE AG (CH) | 2007-06-20 | — | — | EP | disclosed |
| WO-2006034804-A1 | INDOZOLONE DERIVATIVES AS 11B-HSD1 INHIBITORS | F.HOFFMANN-LA ROCHE AG (CH) | 2006-04-06 | — | — | WO | disclosed |
| US-20060069269-A1 | Novel indazolone derivatives useful as 11b-HSD1 inhibitors | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2006-03-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060069269-A1 | Novel indazolone derivatives useful as 11b-HSD1 inhibitors | HSD17B1, HSD11B1, HSD17B7 | NR1I2 79/4885MAPT 2996/4885ATM 2872/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.